Trial Profile
Efficacy and Safety of Paclitaxel/Cyclophosphamide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaRefractory
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Paclitaxel (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 May 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 09 Dec 2016 New trial record